Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis
暂无分享,去创建一个
[1] C. Wanner,et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. , 1999, Kidney international.
[2] C. Wanner,et al. Non-insulin-dependent diabetes mellitus and hypertriglyceridemia impair lipoprotein metabolism in chronic hemodialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.
[3] A. Collins,et al. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. , 1998, The New England journal of medicine.
[4] T. Shoji,et al. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. , 1998, Journal of the American Society of Nephrology : JASN.
[5] D. Serur,et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[6] F. Kronenberg. Homocysteine, lipoprotein(a) and fibrinogen: metabolic risk factors for cardiovascular complications of chronic renal disease , 1998, Current opinion in nephrology and hypertension.
[7] E. Ritz,et al. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[8] F. Kronenberg,et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. , 1997, Journal of the American Society of Nephrology : JASN.
[9] Mai-Szu Wu,et al. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[10] S. Olson,et al. Renal Dysfunction Does Not Alter the Pharmacokinetics or LDL‐Cholesterol Reduction of Atorvastatin , 1997, Journal of clinical pharmacology.
[11] Terje R Pedersen,et al. Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.
[12] J. Himmelfarb,et al. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. , 1997, Journal of the American Society of Nephrology : JASN.
[13] M Nauck,et al. Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein(a) by agarose gel electrophoresis and enzymatic cholesterol staining. , 1995, Clinical chemistry.
[14] D. Sprecher,et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[15] R. Heyka,et al. Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Hemodialysis Patients , 1992, Circulation.
[16] L. Niskanen,et al. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. , 1990, Circulation.
[17] P. Attman,et al. Serum apolipoprotein profile of patients with chronic renal failure. , 1987, Kidney international.
[18] E. Ritz,et al. Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Results of a prospective study. The German Study Group Diabetes and Uremia. , 1993, Nephron.